Primary completion· ClinicalTrials.gov
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Orforglipron History and Updates
159 events · 2019 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
1
FDA Approvals
0
Label Revisions
158
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-10Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Orforglipron since 2019, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (24)
2026
- Results postedOrforglipron Phase 1 PK Study Shows Increased Exposure in Renal Impairment· Jun 9, 2026
- Results postedOrforglipron Phase 1 Study Shows Pharmacokinetic Data in Healthy Participants· May 29, 2026
- Results postedOrforglipron: Clarithromycin Co-administration Increases Exposure in Healthy…· May 27, 2026
- Results postedOrforglipron PK Increases with Severe Hepatic Impairment in Phase 1 Study· May 27, 2026
- Results postedOrforglipron: Phase 1 PK Results for Two Formulations in Healthy Participants· May 27, 2026
- Results postedOrforglipron Phase 1 Study in Healthy Participants Shows 77% Bioavailability· May 27, 2026
- Results postedOrforglipron Phase 1 PK Study Shows High Fecal Excretion in Healthy Males· May 26, 2026
- Results postedOrforglipron Phase 1 Trial Posts Safety and Pharmacokinetic Results· May 26, 2026
- Results postedOrforglipron Phase 1 Trial for Type 2 Diabetes Reports No Drug-Related SAEs· May 26, 2026
- Results postedOrforglipron: Pharmacokinetic Results Posted from Quinidine DDI Study· May 26, 2026
- Results postedOrforglipron Phase 1 Pharmacokinetics Show Food Effect in Healthy Adults· May 26, 2026
- Results postedOrforglipron Exposure Significantly Increases with Cyclosporine…· May 26, 2026
- Results postedOrforglipron Drug-Drug Interaction Study Details Simvastatin PK· May 22, 2026
- Results postedOrforglipron Phase 3 Trial Shows Significant HbA1c Reduction in Type 2 Diabetes· Apr 22, 2026
- FDA approvalOrforglipron (Foundayo) Receives Initial FDA Approval on April 1, 2026· Apr 1, 2026
- Primary completionOrforglipron Phase 3 Trial for Type 2 Diabetes and Obesity Completes Primary…· Mar 16, 2026
2025
- Primary completionOrforglipron Phase 3 Trial for Obesity, Overweight Completes Primary Endpoint· Nov 21, 2025
- Primary completionOrforglipron Phase 3 Trial for Type 2 Diabetes Reaches Primary Completion· Sep 15, 2025
- Primary completionOrforglipron Phase 3 Trial for Type 2 Diabetes Reaches Primary Completion· Aug 22, 2025
- Primary completionOrforglipron Phase 3 Trial for Obesity and Type 2 Diabetes Completes Primary…· Aug 8, 2025
- Primary completionOrforglipron Phase 3 Trial for Obesity/Overweight Completes Primary Phase· Jul 25, 2025
- Primary completionOrforglipron Trial for Obesity in Japanese Adults Reaches Primary Completion· Jun 19, 2025
- Primary completionOrforglipron Phase 3 Long-Term Safety Study in Type 2 Diabetes Completes· Jun 5, 2025
- Primary completionOrforglipron Phase 3 Trial for Type 2 Diabetes Reduces HbA1c by Up to 1.59%· Apr 3, 2025
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Primary completion· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Primary completion· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Primary completion· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Primary completion· ClinicalTrials.gov
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D
Past events
2026
Results posted· ClinicalTrials.gov
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants W
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Results posted· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Results posted· ClinicalTrials.gov
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Phase I Study of LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Healthy Male Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Healthy Overweight and Obese Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes
Results posted· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Results posted· ClinicalTrials.gov
A Multiple-Dose Study of LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Results posted· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
FDA approval· FDA
Sponsor: ELI LILLY AND CO. Class: Type 1 - New Molecular Entity.
Primary completion· ClinicalTrials.gov
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
2025
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D
Primary completion· ClinicalTrials.gov
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Como
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Trial started· ClinicalTrials.gov
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Trial registered· ClinicalTrials.gov
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Trial started· ClinicalTrials.gov
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Primary completion· ClinicalTrials.gov
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Primary completion· ClinicalTrials.gov
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Primary completion· ClinicalTrials.gov
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Trial registered· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Trial started· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Trial started· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Trial started· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Trial started· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Trial registered· ClinicalTrials.gov
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Trial registered· ClinicalTrials.gov
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Primary completion· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
Primary completion· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
2024
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Trial started· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Trial registered· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Trial started· ClinicalTrials.gov
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Trial registered· ClinicalTrials.gov
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Trial started· ClinicalTrials.gov
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Trial registered· ClinicalTrials.gov
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Trial started· ClinicalTrials.gov
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Como
Trial registered· ClinicalTrials.gov
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Como
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Primary completion· ClinicalTrials.gov
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Primary completion· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Trial started· ClinicalTrials.gov
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Trial registered· ClinicalTrials.gov
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
Trial started· ClinicalTrials.gov
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Trial registered· ClinicalTrials.gov
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
Primary completion· ClinicalTrials.gov
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants W
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W
Primary completion· ClinicalTrials.gov
A Phase I Study of LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
Trial registered· ClinicalTrials.gov
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
2023
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With
Trial started· ClinicalTrials.gov
A Phase I Study of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Phase I Study of LY3502970 in Healthy Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Primary completion· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Results posted· ClinicalTrials.gov
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
Trial registered· ClinicalTrials.gov
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Trial started· ClinicalTrials.gov
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Participants With Normal and Impaired Renal Function
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Participants With Normal and Impaired Renal Function
Trial registered· ClinicalTrials.gov
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Trial started· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Trial started· ClinicalTrials.gov
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
Trial registered· ClinicalTrials.gov
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Trial registered· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Trial started· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Trial registered· ClinicalTrials.gov
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight
Trial started· ClinicalTrials.gov
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight
Primary completion· ClinicalTrials.gov
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
2022
Primary completion· ClinicalTrials.gov
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Healthy Overweight and Obese Participants
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Trial started· ClinicalTrials.gov
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Healthy Overweight and Obese Participants
Trial started· ClinicalTrials.gov
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Healthy Overweight and Obese Participants
Primary completion· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Participants
Primary completion· ClinicalTrials.gov
A Multiple-Dose Study of LY3502970 in Healthy Participants
2021
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Trial registered· ClinicalTrials.gov
A Multiple-Dose Study of LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Multiple-Dose Study of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
Trial registered· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Trial started· ClinicalTrials.gov
A Multiple Dose Study of LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Healthy Male Participants
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Healthy Male Participants
2020
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Healthy Male Participants
Primary completion· ClinicalTrials.gov
A Study of LY3502970 in Healthy Participants
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Participants With Type 2 Diabetes
2019
Trial started· ClinicalTrials.gov
A Study of LY3502970 in Healthy Participants
Trial registered· ClinicalTrials.gov
A Study of LY3502970 in Healthy Participants
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.